211 related articles for article (PubMed ID: 19636002)
1. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
Crane CH; Ellis LM; Abbruzzese JL; Amos C; Xiong HQ; Ho L; Evans DB; Tamm EP; Ng C; Pisters PW; Charnsangavej C; Delclos ME; O'Reilly M; Lee JE; Wolff RA
J Clin Oncol; 2006 Mar; 24(7):1145-51. PubMed ID: 16505434
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
[TBL] [Abstract][Full Text] [Related]
4. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
5. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
[TBL] [Abstract][Full Text] [Related]
7. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Sohal DP; Metz JM; Sun W; Giantonio BJ; Plastaras JP; Ginsberg G; Kochman ML; Teitelbaum UR; Harlacker K; Heitjan DF; Feldman MD; Drebin JA; O'Dwyer PJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1485-91. PubMed ID: 23532207
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Javle M; Yu J; Garrett C; Pande A; Kuvshinoff B; Litwin A; Phelan J; Gibbs J; Iyer R
Br J Cancer; 2009 Jun; 100(12):1842-5. PubMed ID: 19491904
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Desai S; Ben-Josef E; Griffith KA; Simeone D; Greenson JK; Francis IR; Hampton J; Colletti L; Chang AE; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1450-5. PubMed ID: 19409732
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Kindler HL; Niedzwiecki D; Hollis D; Sutherland S; Schrag D; Hurwitz H; Innocenti F; Mulcahy MF; O'Reilly E; Wozniak TF; Picus J; Bhargava P; Mayer RJ; Schilsky RL; Goldberg RM
J Clin Oncol; 2010 Aug; 28(22):3617-22. PubMed ID: 20606091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
